CARsgen Therapeutics Updates Share Repurchase Plan and Sees Increased Stake from Key Shareholder
I'm PortAI, I can summarize articles.
CARsgen Therapeutics Holdings Ltd. has updated its share repurchase plan, allowing the buyback of up to 25,461,295 shares over the next 50 trading days, funded by non-IPO raised funds. This reflects the board's belief in the company's undervalued share price and long-term growth potential. Additionally, substantial shareholder YIJIE Biotech Holding Limited has increased its stake, indicating confidence in CARsgen's growth. The latest analyst rating for the stock is a Sell with a price target of HK$14.92.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments